The estimated Net Worth of Haya Taitel is at least $62.5 Thousand dollars as of 12 January 2024. Haya Taitel owns over 9,500 units of Entera Bio Ltd stock worth over $62,505 and over the last few years Haya sold ENTX stock worth over $0.
Sign up
Haya Taitel ENTX stock SEC Form 4 insiders trading
Haya has made over 3 trades of the Entera Bio Ltd stock since 2023, according to the Form 4 filled with the SEC. Most recently Haya bought 9,500 units of ENTX stock worth $9,405 on 12 January 2024.
The largest trade Haya's ever made was buying 18,000 units of Entera Bio Ltd stock on 22 August 2023 worth over $11,160. On average, Haya trades about 5,853 units every 24 days since 2023. As of 12 January 2024 Haya still owns at least 35,115 units of Entera Bio Ltd stock.
You can see the complete history of Haya Taitel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Haya Taitel's mailing address?
Haya's mailing address filed with the SEC is KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, L3, 9112002.
Insiders trading at Entera Bio Ltd
Over the last 3 years, insiders at Entera Bio Ltd have traded over $0 worth of Entera Bio Ltd stock and bought 467,822 units worth $484,536 . The most active insiders traders include Gerald M Lieberman, Miranda Jayne Toledano, and Sean Ellis. On average, Entera Bio Ltd executives and independent directors trade stock every 32 days with the average trade being worth of $36,205. The most recent stock trade was executed by Haya Taitel on 12 January 2024, trading 9,500 units of ENTX stock currently worth $9,405.
What does Entera Bio Ltd's logo look like?
Complete history of Haya Taitel stock trades at Entera Bio Ltd
Entera Bio Ltd executives and stock owners
Entera Bio Ltd executives and other stock owners filed with the SEC include:
-
Phillip Schwartz,
President of Research and Development -
Gerald Lieberman,
Independent Chairman of the Board -
Arthur Santora,
Chief Medical Officer -
Dr. Phillip Schwartz Ph.D.,
Exec. VP, Pres of R&D and Director -
Roger Garceau,
Chief Executive Officer, Director -
Hillel Galitzer,
Chief Operating Officer -
Dr. Hillel Galitzer,
Chief Operating Officer -
Dr. Arthur C. Santora II, M.D., Ph.D.,
Chief Medical Officer -
Kiryat Hadassah,
IR Contact Officer -
Miranda Toledano,
Independent Director -
Gerald Ostrov,
Independent Director -
Faith Charles,
Independent Director -
Yonatan Malca,
Director -
Sean Ellis,
Director -
Zeev Bronfeld,
Director -
Jonathan Lieber,
Chief Financial Officer - U.S.-based -
Dana Yaacov-Garbeli,
Chief Financial Officer -
Dr. Roger J. Garceau,
Chief Devel. Advisor & Director -
Ramesh Ratan,
U.S. Chief Financial Officer -
Dana Yaacov-Garbeli CPA,
Chief Financial Officer -
Dr. Spiros Jamas,
CEO & Director -
Haya Taitel,
Director -
Ramesh Ratan,
U.S.based CFO -
Spiros Jamas,
Chief Executive Officer -
Ron Mayron,
Director